Ionis Pharmaceuticals Inc

Healthcare · Biotechnology

44.50$ +1.6% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Ionis Pharmaceuticals Inc (IONS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 3,524 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet IONS
Line item	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	101	118	96	103	183	417	439	335	208	166	256	259	574	657	550	485	546	847	956	956	912	1,322	2,668	3,233	2,390	2,612	2,534	2,990	3,004	3,524
Current Assets	79	89	63	59	133	329	320	240	126	106	206	207	518	596	483	360	423	736	837	837	798	1,168	2,208	2,721	2,130	2,345	2,203	2,642	2,620	2,990
Cash	37	38	28	35	40	127	102	33	27	3.7	115	139	218	105	70	65	374	657	729	779	665	1,023	2,084	2,500	1,892	2,115	276	399	242	372
Cash & Short-Term Investments	37	38	28	53	127	312	289	216	104	94	193	194	491	574	472	344	408	709	811	804	668	1,023	2,084	2,500	1,892	2,115	1,997	2,331	2,298	2,677
Receivables	–	–	3.5	5.4	3.3	10	15	2.7	10	3.9	2.4	6.2	4.1	11	1.2	6.9	0.5	11	3.9	11	108	63	13	63	76	62	26	98	92	66
Inventory	–	–	–	–	–	–	11	14	2.7	1.0	0.9	2.8	2.7	2.8	2.5	4.1	6.1	8.0	6.3	6.9	7.5	10.0	8.6	18	22	25	22	7.4	13	10
Property, Plant & Equipment	–	–	–	–	23	28	59	35	28	9.1	7.2	7.1	17	27	36	97	91	86	89	90	93	122	132	154	181	178	74	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–
Intangible Assets	6.2	7.5	9.1	11	14	49	50	51	45	43	38	37	33	30	16	16	25	20	20	19	20	22	24	26	28	29	–	–	–	–
Total Liabilities	43	83	100	102	117	194	283	268	281	164	158	249	470	355	306	313	363	469	698	755	813	903	1,481	1,548	1,547	1,840	1,961	2,603	2,415	3,035
Current Liabilities	23	27	23	15	15	48	76	46	43	24	25	62	125	111	106	76	74	98	115	149	134	225	280	273	290	241	312	448	309	782
Short-Term Debt	6.2	2.3	3.6	3.9	4.6	9.8	21	16	11	7.8	7.5	7.2	2.1	4.3	5.6	3.4	4.9	4.4	2.9	9.0	1.2	1.6	14	2.0	293	3.5	7.5	53	9.3	453
Accounts Payable	2.4	2.8	3.0	3.1	2.2	6.1	5.5	3.7	7.0	2.1	4.3	4.5	5.7	4.7	6.5	8.3	10	11	18	28	21	25	29	16	17	12	18	26	43	28
Long-Term Debt	–	–	–	–	102	126	193	213	237	140	133	163	172	137	143	215	222	228	455	398	501	593	628	770	516	1,221	1,183	1,230	1,245	1,347
Shareholders' Equity	58	35	-4.2	0.8	66	223	155	67	-72	2.7	69	0.9	67	292	245	171	183	378	258	201	100	419	1,187	1,685	843	772	573	387	588	489
Retained Earnings	-123	-154	-197	-257	-311	-387	-460	-556	-698	-771	-817	-828	-840	-696	-757	-841	-907	-968	-1,007	-1,095	-1,181	-1,187	-967	-708	-1,249	-1,160	-1,430	-1,796	-2,250	-2,631
Shares Outstanding	25	27	27	29	37	44	54	55	57	63	74	84	95	98	99	100	101	111	118	120	121	126	134	143	140	141	142	143	150	160

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings